CD274 and non-small cell lung carcinoma: Likewise, only approximately 15 to 18% of patients were tested for PD-L1 in 2015–2016; however, since the availability of anti–programmed death-1/PD-L1 immune checkpoint inhibitors for the treatment of NSCLC, testing for this biomarker has become part of the routine practice at IPO-Porto for patients with NSCLC able to receive a SACT regimen.